Your browser doesn't support javascript.
loading
Association of Structural Forms of 17q21.31 with the Risk of Progressive Supranuclear Palsy and MAPT Sub-haplotypes.
Wang, Hui; Chang, Timothy S; Dombroski, Beth A; Cheng, Po-Liang; Si, Ya-Qin; Tucci, Albert; Patil, Vishakha; Valiente-Banuet, Leopoldo; Farrell, Kurt; Mclean, Catriona; Molina-Porcel, Laura; Alex, Rajput; Paul De Deyn, Peter; Le Bastard, Nathalie; Gearing, Marla; Donker Kaat, Laura; Van Swieten, John C; Dopper, Elise; Ghetti, Bernardino F; Newell, Kathy L; Troakes, Claire; G de Yébenes, Justo; Rábano-Gutierrez, Alberto; Meller, Tina; Oertel, Wolfgang H; Respondek, Gesine; Stamelou, Maria; Arzberger, Thomas; Roeber, Sigrun; Müller, Ulrich; Hopfner, Franziska; Pastor, Pau; Brice, Alexis; Durr, Alexandra; Ber, Isabelle Le; Beach, Thomas G; Serrano, Geidy E; Hazrati, Lili-Naz; Litvan, Irene; Rademakers, Rosa; Ross, Owen A; Galasko, Douglas; Boxer, Adam L; Miller, Bruce L; Seeley, Willian W; Van Deerlin, Vivianna M; Lee, Edward B; White, Charles L; Morris, Huw R; de Silva, Rohan.
Afiliación
  • Wang H; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Chang TS; Penn Neurodegeneration Genomics Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Dombroski BA; Movement Disorders Programs, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Cheng PL; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Si YQ; Penn Neurodegeneration Genomics Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Tucci A; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Patil V; Penn Neurodegeneration Genomics Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Valiente-Banuet L; Bioinformatics Research Center, North Carolina State University, NC, USA.
  • Farrell K; Bioinformatics Research Center, North Carolina State University, NC, USA.
  • Mclean C; Movement Disorders Programs, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Molina-Porcel L; Movement Disorders Programs, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Alex R; Department of Pathology, Department of Artificial Intelligence & Human Health, Nash Family, Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain, Institute, Neuropathology Brain Bank & Research CoRE, Icahn School of Medicine at Mount Sinai, New York, NY,
  • Paul De Deyn P; Victorian Brain Bank, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.
  • Le Bastard N; Alzheimer's disease and other cognitive disorders unit. Neurology Service, Hospital Clínic, Fundació Recerca Clínic Barcelona (FRCB). Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
  • Gearing M; Neurological Tissue Bank of the Biobanc-Hospital Clínic-IDIBAPS, Barcelona, Spain.
  • Donker Kaat L; Movement Disorders Program, Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Van Swieten JC; Laboratory of Neurochemistry and Behavior, Experimental Neurobiology Unit, University of Antwerp, Wilrijk (Antwerp), Belgium.
  • Dopper E; Department of Neurology, University Medical Center Groningen, NL-9713 AV Groningen, Netherlands.
  • Ghetti BF; Fujirebio Europe NV, Technologiepark 6, 9052 Gent, Belgium.
  • Newell KL; Department of Pathology and Laboratory Medicine and Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
  • Troakes C; Netherlands Brain Bank and Erasmus University, Netherlands.
  • G de Yébenes J; Netherlands Brain Bank and Erasmus University, Netherlands.
  • Rábano-Gutierrez A; Netherlands Brain Bank and Erasmus University, Netherlands.
  • Meller T; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Oertel WH; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Respondek G; London Neurodegenerative Diseases Brain Bank, King's College London, London, UK.
  • Stamelou M; Autonomous University of Madrid, Madrid, Spain.
  • Arzberger T; Fundación CIEN (Centro de Investigación de Enfermedades Neurológicas) - Centro Alzheimer Fundación Reina Sofía, Madrid, Spain.
  • Roeber S; Department of Neurology, Philipps-Universität, Marburg, Germany.
  • Müller U; Department of Neurology, Philipps-Universität, Marburg, Germany.
  • Hopfner F; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Pastor P; Parkinson's disease and Movement Disorders Department, HYGEIA Hospital, Athens, Greece.
  • Brice A; European University of Cyprus, Nicosia, Cyprus.
  • Durr A; Department of Psychiatry and Psychotherapy, University Hospital Munich, Ludwig-Maximilians-University Munich, Germany.
  • Ber IL; Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Germany.
  • Beach TG; German Brain Bank, Neurobiobank Munich, Germany.
  • Serrano GE; German Brain Bank, Neurobiobank Munich, Germany.
  • Hazrati LN; Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; and Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
  • Litvan I; Unit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
  • Rademakers R; Neurosciences, The Germans Trias i Pujol Research Institute (IGTP) Badalona, Badalona, Spain.
  • Ross OA; Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, APHP - Hôpital Pitié-Salpêtrière, Paris, France.
  • Galasko D; Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, APHP - Hôpital Pitié-Salpêtrière, Paris, France.
  • Boxer AL; Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, APHP - Hôpital Pitié-Salpêtrière, Paris, France.
  • Miller BL; Banner Sun Health Research Institute, Sun City, AZ, USA.
  • Seeley WW; Banner Sun Health Research Institute, Sun City, AZ, USA.
  • Van Deerlin VM; University McGill, Montreal, Quebec, Canada.
  • Lee EB; Department of Neuroscience, University of California, San Diego, CA, USA.
  • White CL; VIB Center for Molecular Neurology, University of Antwerp, Belgium.
  • Morris HR; Department of Neuroscience, Mayo Clinic Jacksonville, FL, USA.
  • de Silva R; Department of Neuroscience, Mayo Clinic Jacksonville, FL, USA.
medRxiv ; 2024 Feb 28.
Article en En | MEDLINE | ID: mdl-38464214
ABSTRACT
Importance The chromosome 17q21.31 region, containing a 900 Kb inversion that defines H1 and H2 haplotypes, represents the strongest genetic risk locus in progressive supranuclear palsy (PSP). In addition to H1 and H2, various structural forms of 17q21.31, characterized by the copy number of α, ß, and γ duplications, have been identified. However, the specific effect of each structural form on the risk of PSP has never been evaluated in a large cohort study.

Objective:

To assess the association of different structural forms of 17q.21.31, defined by the copy numbers of α, ß, and γ duplications, with the risk of PSP and MAPT sub-haplotypes. Design setting and

participants:

Utilizing whole genome sequencing data of 1,684 (1,386 autopsy confirmed) individuals with PSP and 2,392 control subjects, a case-control study was conducted to investigate the association of copy numbers of α, ß, and γ duplications and structural forms of 17q21.31 with the risk of PSP. All study subjects were selected from the Alzheimer's Disease Sequencing Project (ADSP) Umbrella NG00067.v7. Data were analyzed between March 2022 and November 2023. Main outcomes and

measures:

The main outcomes were the risk (odds ratios [ORs]) for PSP with 95% CIs. Risks for PSP were evaluated by logistic regression models.

Results:

The copy numbers of α and ß were associated with the risk of PSP only due to their correlation with H1 and H2, while the copy number of γ was independently associated with the increased risk of PSP. Each additional duplication of γ was associated with 1.10 (95% CI, 1.04-1.17; P = 0.0018) fold of increased risk of PSP when conditioning H1 and H2. For the H1 haplotype, addition γ duplications displayed a higher odds ratio for PSP the odds ratio increases from 1.21 (95%CI 1.10-1.33, P = 5.47 × 10-5) for H1ß1γ1 to 1.29 (95%CI 1.16-1.43, P = 1.35 × 10-6) for H1ß1γ2, 1.45 (95%CI 1.27-1.65, P = 3.94 × 10-8) for H1ß1γ3, and 1.57 (95%CI 1.10-2.26, P = 1.35 × 10-2) for H1ß1γ4. Moreover, H1ß1γ3 is in linkage disequilibrium with H1c (R2 = 0.31), a widely recognized MAPT sub-haplotype associated with increased risk of PSP. The proportion of MAPT sub-haplotypes associated with increased risk of PSP (i.e., H1c, H1d, H1g, H1o, and H1h) increased from 34% in H1ß1γ1 to 77% in H1ß1γ4. Conclusions and relevance This study revealed that the copy number of γ was associated with the risk of PSP independently from H1 and H2. The H1 haplotype with more γ duplications showed a higher odds ratio for PSP and were associated with MAPT sub-haplotypes with increased risk of PSP. These findings expand our understanding of how the complex structure at 17q21.31 affect the risk of PSP.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: MedRxiv Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: MedRxiv Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos